Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? (Q80962290)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15526015%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15526015%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15526015%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Artz A

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15526015%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Stock W

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15526015%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15526015%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15526015%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15526015%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15526015%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

31-33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15526015%20AND%20SRC:MED&resulttype=core&format=json

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

A new era of antifungal therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Bone-marrow transplantation (first of two parts).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Endogenous stem cell repopulation resulting in mixed hematopoietic chimerism following total body irradiation and marrow transplantation for acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403594

7 January 2021